Zymeworks Raises 2026 Revenue Guidance to $337M-$351M Following $250M Jazz Milestone
ZYME sits 93% above its 52-week low of $16.003.
Summary
Zymeworks posted Q3 revenue of $256.5M and net income of $173.7M, driven by the $250M Jazz milestone, and raised 2026 revenue guidance to $337M-$351M while stating it has no current plans for more equity issuance.
Key Events · Earnings and Guidance · ZYME
-
Guidance Raised Sharply for 2026
Total revenue guidance rises to $337M-$351M from $278M-$292M, and Adjusted EBITDA to $176M-$190M from $114M-$128M, excluding future transactions and contingent on HSR clearance for the Roche collaboration.
-
Q3 Profit on $250M Jazz Milestone
Total revenue reached $256.5M versus $27.6M a year earlier, including the $250.0M milestone earned after FDA approval of Ziihera in first-line HER2-positive GEA; net income was $173.7M, or $2.28 per diluted share.
-
No New Equity Planned
To fund the Theravance acquisition and buybacks, Zymeworks accessed $600M of non-dilutive financing in 2026 at a weighted average cost below 10%, and it states no current plans for additional equity issuances.
-
Buybacks Total $279.8M Since 2024
In the first nine months of 2026 the company repurchased 5,737,790 shares for $140.4M at an average of $24.48, and cumulatively since August 2024, 12,940,827 shares for $279.8M; about 69.0M shares were outstanding as of November 6, 2026.
Analysis · ZYME · Life Sciences
A $250M Jazz milestone tied to Ziihera's first-line GEA approval powered Zymeworks to a $173.7M third-quarter profit on $256.5M of revenue. The guidance raise matters more than the headline beat: full-year revenue is now $337M-$351M versus $278M-$292M, and Adjusted EBITDA $176M-$190M versus $114M-$128M, marking a step change in the earnings base rather than a one-off. Management also said it has no current plans for additional equity issuances, having funded the $929M Theravance deal with $600M of non-dilutive royalty-backed and senior notes. With the stock near its 52-week high of $31.49, the risk is that the milestone was already anticipated; the durable test is whether YUPELRI and royalty cash flows hold up once the one-time $250M drops out of the comparison.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZYME was trading at $30.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $16.00 to $31.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.